Bayer drops hemophilia candidate BAY 86-6150 on safety concerns

German drug major Bayer (BAYN: DE) said on Friday (May 3) that it has discontinued a Phase II/III trial evaluating the efficacy and safety of BAY 86-6150 in people with hemophilia A and hemophilia B with inhibitors has been discontinued.

The company said that the hope that BAY 86-6150 might help patients with inhibitors to achieve better control of their disease could not be fulfilled due to the detection of a neutralizing antibody in the trial.

"Patient safety is our primary concern when designing clinical trials and evaluating BAY 86-6150,” said Kemal Malik, a member of the Bayer HealthCare executive committee and head of global development, adding: “Due to safety concerns, we are discontinuing the BAY 86-6150 trial as a precautionary measure.”